Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gross Profit (2016 - 2025)

Historic Gross Profit for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q3 2025 value amounting to $53.3 million.

  • Vanda Pharmaceuticals' Gross Profit rose 1819.07% to $53.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.3 million, marking a year-over-year increase of 1208.85%. This contributed to the annual value of $187.5 million for FY2024, which is 540.59% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Gross Profit stood at $53.3 million, which was up 1819.07% from $49.9 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year Gross Profit high stood at $63.3 million for Q3 2021, and its period low was $35.8 million during Q3 2023.
  • For the 5-year period, Vanda Pharmaceuticals' Gross Profit averaged around $52.0 million, with its median value being $53.3 million (2025).
  • In the last 5 years, Vanda Pharmaceuticals' Gross Profit crashed by 3940.13% in 2023 and then surged by 2614.68% in 2024.
  • Vanda Pharmaceuticals' Gross Profit (Quarter) stood at $61.8 million in 2021, then decreased by 5.73% to $58.2 million in 2022, then fell by 28.21% to $41.8 million in 2023, then increased by 21.01% to $50.6 million in 2024, then rose by 5.35% to $53.3 million in 2025.
  • Its Gross Profit was $53.3 million in Q3 2025, compared to $49.9 million in Q2 2025 and $46.5 million in Q1 2025.